Browse studies

Find your next paid study

21 recruiting studies matching your filters

A Phase 2 Trial of Leflunomide, Pomalidomide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma

This phase II trial studies how well leflunomide, pomalidomide, and dexamethasone work for the treatment of multiple myeloma that has come back (relapsed) or d…

Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma

Estimated

~$10 – $6,250

City of Hope Medical CenterNCT04508790

Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

This study assesses neurocognitive outcomes after receiving radiation therapy to the brain (whole brain radiation therapy) in patients with blood cancers (hema…

Central Nervous System LymphomaHematopoietic and Lymphoid Cell NeoplasmLeukemia+3 more

Estimated

~$10 – $750

M.D. Anderson Cancer CenterNCT05011045

Phase 1

Phase 1 Trial of 111Indium/225Actinium-DOTA-Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma

This phase I trial tests the safety, side effects, and best dose of actinium Ac 225-DOTA-daratumumab (225Ac-DOTA-daratumumab) in combination with daratumumab a…

Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma

Estimated

~$10 – $6,250

City of Hope Medical CenterNCT05363111

Phase 2

A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)

The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in co…

Plasma Cell Myeloma Refractory

Phase I Study to Evaluate Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CS1-Targeting, Hinge-Optimized, 41BB-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in Adult Patients With CS1+ Multiple Myeloma

This phase I trial studies the side effects and best dose of CS1-chimeric antigen receptor (CAR) T therapy after chemotherapy in treating patients who have CS1…

Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma

Estimated

~$10 – $6,250

City of Hope Medical CenterNCT03710421

Observational

Improving Host Factors in Patients With Monoclonal Gammopathies and Other Hematologic Disorders

This clinical trial investigates the effect of non-chemotherapeutic interventions in patients with multiple myeloma or MDS. Non-chemotherapeutic interventions …

Plasma Cell MyelomaRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma+1 more

Estimated

~$10 – $7,500

Roswell Park Cancer InstituteNCT05312255

Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma (ORIGIN Study)

The goal of this study is to find markers that may help to predict why some patients who have monoclonal gammopathy of unknown significance (MGUS) or smolderin…

Monoclonal Gammopathy of Undetermined SignificanceSmoldering Plasma Cell Myeloma

Estimated

~$10 – $750

M.D. Anderson Cancer CenterNCT02726750

Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies

This study examines the quality of life in patients with monoclonal gammopathy of unknown significance and smoldering multiple myeloma. Collecting quality of l…

Monoclonal Gammopathy of Undetermined SignificanceSmoldering Plasma Cell Myeloma

Estimated

~$10 – $750

M.D. Anderson Cancer CenterNCT05136807

Phase 1

A First-in-human, Open-label, Phase 1 Study to Evaluate the Safety, Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of Subcutaneous SAR446523, an Anti-GPRC5D ADCC-enhanced Monoclonal Antibody, in Participants With Relapsed/Refractory Multiple Myeloma

This is a first-in-human study of SAR446523 conducted in patients with RRMM. The study consists of two parts: Dose escalation (Part A): In this part, up to s…

Plasma Cell Myeloma Refractory

Estimated

~$10 – $7,500

SanofiNCT06630806